Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum HFY15
- Development stage
- Preclinical
- Lead developer
- Chongqing University of Education
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum HFY15 is a specific strain of probiotic bacteria that was originally isolated from naturally fermented yak yogurt in Sichuan, China. [3] This biologic agent is being investigated in preclinical studies for several therapeutic purposes, including secondary osteoporosis, acute liver injury, and lupus nephritis. [1, 3, 6] Its mechanism of action involves antioxidant, anti-inflammatory, and anti-apoptotic effects, which are mediated through the regulation of multiple biological pathways like the TGF-β1, Wnt/β-catenin, and OPG/RANK/RANKL signaling pathways. [1, 3, 6] Research in animal models has demonstrated its ability to protect tissues from damage and reduce levels of inflammatory cytokines such as IL-6, TNF-α, and IFN-γ. [5, 6] It is currently considered a research compound primarily studied in academic settings, such as the Chongqing University of Education, and does not have a commercial brand name. [4]
- Other names
- 植物乳杆菌HFY15
Beyond the preview
Go deeper on lactobacillus plantarum HFY15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum HFY15.